MorphoSys AG

Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL

Role: collaborator

Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma

Role: collaborator

Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Role: collaborator

MOR202 for Refractory MN

Role: collaborator

Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL

Role: lead

Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL)

Role: lead

Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL

Role: lead

Lenalidomide Monotherapy in R/R DLBCL

Role: lead

Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors

Role: collaborator

Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi

Role: lead

A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma

Role: lead

Observational Retrospective Cohort Study of Systemic Therapies for R/R DLBCL

Role: lead

Expanded Access Program for Tafasitamab (MOR00208) in R/R DLBCL

Role: lead

Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL)

Role: lead

First in Human of Single and Multiple Doses of MOR106

Role: collaborator

Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis

Role: lead

Safety and Preliminary Efficacy of MOR103 in Patients With Active Rheumatoid Arthritis

Role: lead